| Specialized immunoassay kit supplier | Amyloid-beta 42/40 ratio | Plasma or cerebrospinal fluid | High-sensitivity immunoassay | Lot-specific calibration, lower limit of quantification, precision, interference, and matrix recovery | 2–6 weeks for research supply; longer for customized validation | Approximately US$35–120 per research test equivalent; kit pricing varies by format | Usually research-use-only unless a specific regulated claim is documented; request ISO 13485 status and lot-release records | Cold-chain requirements may apply; customs documentation and temperature-excursion procedures are important | Confirm ratio calculation, reference intervals, calibrator traceability, stability data, and availability of replacement lots |
| Ultra-sensitive digital immunoassay supplier | Phosphorylated tau, especially p-tau181 or p-tau217 | Plasma, serum, or cerebrospinal fluid | Single-molecule or digital bead-based immunoassay | Low-picomolar sensitivity, dilutional linearity, cross-reactivity, precision, and clinical cut-off performance | 4–10 weeks for kits; 6–16 weeks for service testing | Approximately US$60–220 per test equivalent; higher for clinical-grade service workflows | Many offerings remain research-use-only; clinical use requires jurisdiction-specific evidence and labeling | Instrument access, trained operators, reagent shelf life, and service coverage can limit cross-border deployment | Request antibody-epitope information, method comparison against an established reference method, and population-specific validation |
| Automated clinical-laboratory assay supplier | Total tau or phosphorylated tau panel | Primarily cerebrospinal fluid; plasma availability depends on assay | Automated chemiluminescent or electrochemiluminescent assay | Reproducibility, onboard stability, carryover, calibration verification, and laboratory reference intervals | 1–4 weeks for reagent delivery; same-day to several days for routine testing after implementation | Approximately US$25–100 per test equivalent, excluding analyzer and labor costs | Potentially higher regulatory maturity; verify market-specific registration, intended use, and post-market obligations | Best suited to laboratories with compatible analyzers, local technical support, and validated import channels | Check analyzer compatibility, minimum order quantities, service-level commitments, software updates, and local representation |
| Multiplex neurodegeneration panel supplier | p-tau, amyloid-beta, neurofilament light, and GFAP | Plasma or serum | Multiplex bead-based or electrochemiluminescent platform | Panel-level precision, analyte interaction, batch effects, cross-reactivity, and missing-value rate | 3–8 weeks for kits; 2–8 weeks for outsourced testing | Approximately US$80–300 per panel equivalent | Generally research-use-only; validation must address each analyte and the combined interpretation model | Consolidated shipping reduces cost, but one temperature excursion can affect several analytes in the same panel | Ask for individual analyte certificates, panel-specific quality controls, sample volume requirements, and data-export formats |
| Mass-spectrometry assay service provider | Amyloid-beta isoforms and phosphorylated tau peptides | Plasma or cerebrospinal fluid | Targeted liquid chromatography–tandem mass spectrometry | Peptide specificity, isotope-labeled internal standards, extraction recovery, calibration model, and carryover | 4–12 weeks, depending on method development and batch size | Approximately US$120–450 per sample; development and validation fees may be additional | Strong analytical specificity; regulatory acceptability depends on validation, intended use, and laboratory quality system | Cross-border shipment of human specimens may require permits, material-transfer agreements, and import declarations | Review raw-data access, reference standards, chain of custody, method-transfer package, and long-term sample retention policy |
| Neurofilament and glial-marker assay supplier | Neurofilament light and GFAP | Plasma, serum, or cerebrospinal fluid | High-sensitivity immunoassay | Age-related reference data, hemolysis and lipemia effects, precision, and freeze–thaw stability | 2–6 weeks for kits; 1–4 weeks for established service testing | Approximately US$35–160 per analyte or test equivalent | Most products are research-use-only; clinical interpretation requires demographic and disease-context validation | Usually easier to ship than fragile multiplex panels, but temperature control and local customs clearance remain relevant | Confirm whether results are intended for AD-specific use or general neuroaxonal injury monitoring |
| Clinical biomarker testing laboratory | Integrated AD biomarker interpretation panel | Plasma or cerebrospinal fluid collected under defined protocols | Validated immunoassay or mass-spectrometry workflow | Reportable range, assay precision, clinical sensitivity and specificity, cut-off verification, and proficiency testing | 7–21 business days after sample receipt | Approximately US$200–700 per sample, excluding collection, shipping, and medical interpretation | Look for ISO 15189, CAP-style accreditation, or equivalent national laboratory recognition; verify scope rather than assuming full coverage | Patient-sample export, privacy rules, consent, customs permits, and temperature-controlled courier service must be addressed before contracting | Review sample rejection criteria, report format, data privacy terms, result ownership, and escalation procedures for delayed samples |
| Custom assay development partner | Client-defined combinations of amyloid, tau, NfL, GFAP, or related markers | Plasma, serum, cerebrospinal fluid, or other validated matrices | Immunoassay, multiplex assay, or targeted mass spectrometry | Full validation plan covering specificity, accuracy, precision, stability, robustness, and method transfer | 3–9 months for development; longer if clinical validation is required | Approximately US$25,000–250,000 for development, before per-sample testing costs | Quality-system maturity and regulatory strategy should be assessed before signing a development contract | Define ownership of methods, antibodies, calibrators, data, regulatory documents, and technology-transfer materials | Use milestone-based purchasing, acceptance criteria, change-control terms, and a clear business-continuity plan |
| Bioreagent and reference-material supplier | Recombinant proteins, peptides, antibodies, calibrators, and quality-control materials | Not applicable; materials support assay development and control programs | Purified reference materials and immunoreagents | Purity, identity, concentration assignment, homogeneity, stability, and certificate-of-analysis completeness | 1–8 weeks; custom reference materials may require several months | Approximately US$250–5,000 per material, depending on quantity and characterization | Usually not a clinical diagnostic product; suitability must be established by the purchasing laboratory | Dry-ice or refrigerated shipping may be required; import classification and biological-material declarations should be checked | Verify lot comparability, assigned value uncertainty, storage conditions, retest date, and replacement-lot bridging requirements |
| Contract research organization | AD biomarker testing within observational or interventional studies | Centralized plasma, serum, cerebrospinal fluid, or imaging-linked specimens | Validated ligand-binding assay, digital immunoassay, or mass spectrometry | Protocol adherence, blinded QC, sample tracking, assay drift monitoring, and audit-ready documentation | 4–16 weeks for setup; study testing is scheduled by batch and protocol | Approximately US$150–900 per sample, plus study setup, logistics, and data-management fees | GCP, GLP, ISO 17025, ISO 15189, or equivalent capabilities may apply depending on the study design | Requires harmonized collection kits, international courier coordination, import permits, and country-specific privacy controls | Assess global site coverage, disaster recovery, audit rights, electronic data transfer, and sample reconciliation procedures |
